{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:50:39Z","timestamp":1781733039086,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.adro.2025.101850","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:47:57Z","timestamp":1751572077000},"page":"101850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-0135","authenticated-orcid":false,"given":"Michael","family":"Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Chlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Keats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Glyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101850_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.21037\/tau.2017.12.37","article-title":"Image-guided radiotherapy for prostate cancer","volume":"7","author":"Dang","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.adro.2025.101850_bib0002","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/cncr.28213","article-title":"Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation","volume":"119","author":"Nguyen","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101850_bib0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2025.101850_bib0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high-and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fonc.2019.00217","article-title":"Phase 2 multicenter study of Gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (prometheus)","volume":"9","author":"Pryor","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0007","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.euo.2024.01.008","article-title":"Prostate virtual high-dose-rate brachytherapy boost: 5-year results from the PROMETHEUS prospective multicentre trial","volume":"7","author":"Wegener","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101850_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2015.00151","article-title":"Dysuria following stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Janowski","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0011","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4511-6","article-title":"PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: The PROMETHEUS study protocol","volume":"18","author":"Richardson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2025.101850_bib0013","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jmrs.485","article-title":"Visualising the urethra for prostate radiotherapy planning","volume":"68","author":"Richardson","year":"2021","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.adro.2025.101850_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.softx.2024.102010","article-title":"PyDicer: An open-source python library for conversion and analysis of radiotherapy DICOM data","volume":"29","author":"Chlap","year":"2025","journal-title":"SoftwareX"},{"key":"10.1016\/j.adro.2025.101850_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijrobp.2020.12.034","article-title":"Stereotactic body radiation therapy and high-dose-rate brachytherapy boost in combination with intensity modulated radiation therapy for localized prostate cancer: A single-institution propensity score matched analysis","volume":"110","author":"Chen","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euros.2023.06.003","article-title":"A Multicenter phase 2 study of Ultrahypofractionated stereotactic boost after external beam radiotherapy in intermediate-risk prostate carcinoma: A very long-term analysis of the CKNO-PRO trial","volume":"54","author":"Pasquier","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.adro.2025.101850_bib0017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.adro.2019.03.015","article-title":"Results of a prospective dose escalation study of linear accelerator-based virtual brachytherapy (BOOSTER) for prostate cancer; virtual HDR brachytherapy for prostate cancer","volume":"4","author":"Eade","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030731","article-title":"TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol","volume":"9","author":"Martin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.adro.2025.101850_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","article-title":"Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial","volume":"116","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2019.01.088","article-title":"Voxel-based analysis for identification of urethrovesical subregions predicting urinary toxicity after prostate cancer radiation therapy","volume":"104","author":"Mylona","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-014-0241-3","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u2265 50 cm3)","volume":"9","author":"Janowski","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0022","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101850_bib0023","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fonc.2020.00555","article-title":"Urinary morbidity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate cancer following transurethral resection of the prostate (TURP)","volume":"10","author":"Pepin","year":"2020","journal-title":"Front Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245210942500137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245210942500137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:39:35Z","timestamp":1757687975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245210942500137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S245210942500137X"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101850","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101850"}}